Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference
San Diego-based Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event features a fireside chat with CEO Jonathan E. Lim and CFO David M. Chacko on September 10, 2021, at 4:15 PM ET. The live webcast can be accessed on the company’s website, with an archived replay available for 30 days post-event. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer through innovative treatments.
- None.
- None.
Insights
Analyzing...
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat beginning at 4:15 PM Eastern Time on Friday, September 10, 2021.
Registration for the live webcast is available at Morganstanley.webcasts. A live webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When is Erasca participating in the Morgan Stanley Healthcare Conference?
Who will represent Erasca in the fireside chat at the conference?
What time is Erasca's fireside chat scheduled?
How can I access the live webcast of Erasca's presentation?
Will there be a replay available for Erasca's conference presentation?
